Pharma Capital

MaxCyte boss Doerfler excited by gene-editing licence deal

Doug Doerfler, chief executive of MaxCyte, runs through the firm's first commercial licence deal in the gene-editing space.
Under the deal, CRISPR Therapeutics (NASDAQ:CRSP) and its joint-venture with Bayer AG, a company called Casebia Therapeutics, have picked up a licence to use MaxCyte’s technology.
CRISPR Therapeutics and Casebia will get non-exclusive commercial-use rights to MaxCyte's cell engineering platform.
"It's a very exciting time for the company and it's really a pleasure to be working with this advanced group that’s working in the area of inherited blood disorders," said Doerfler.

 

View full MXCT profile

MaxCyte Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.